A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

Conclusions. The RSV-PreF vaccine elicited rapid RSV neutralizing antibody responses in healthy young men, with an acceptable adverse event profile.

Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Langley, J. M., Aggarwal, N., Toma, A., Halperin, S. A., McNeil, S. A., Fissette, L., Dewe, W., Leyssen, M., Toussaint, J.-F., Dieussaert, I. Tags: VIRUSES Source Type: research